Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
Inhaled drug shows promise for managing tough Lung-Heart condition
Disease control CompletedThis study looked at the long-term safety of an inhaled medication called treprostinil palmitil (TPIP) for people with pulmonary hypertension caused by interstitial lung disease. Thirty-one adults who completed a previous study took part. The main goal was to check for side effec…
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New inhaled drug shows promise for rare lung condition
Disease control CompletedThis phase 2b trial tested an inhaled powder form of treprostinil palmitil in 102 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. The study compared the drug to a placebo to see if it could lower lung…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill for cystic fibrosis moves to human testing
Disease control CompletedThis study tested an experimental pill called brensocatib in 29 adults with cystic fibrosis. The main goals were to see how the drug behaves in the body and whether it is safe compared to a placebo over 4 weeks. Participants took the pill once daily, and researchers measured drug…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Inhaled antibiotic shows promise against stubborn lung infection
Disease control CompletedThis study tested whether adding an inhaled antibiotic (ALIS) to standard oral antibiotics helps adults with a new diagnosis of a hard-to-treat lung infection caused by MAC bacteria. About 425 adults took part. The main goal was to see if the combination improved breathing sympto…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill could cut dangerous lung Flare-Ups in bronchiectasis patients
Disease control CompletedThis large Phase 3 trial tested whether a daily pill called brensocatib can reduce the number of lung infections (called pulmonary exacerbations) in people with non-CF bronchiectasis, a chronic lung condition. Over 1,700 adults and adolescents took either 10 mg, 25 mg of brensoca…
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill aims to ease stuffy nose and facial pain for sinusitis sufferers
Symptom relief CompletedThis study tested an experimental drug called brensocatib in 288 adults with long-term sinus inflammation but no nasal polyps. Participants took either 10 mg, 40 mg, or a placebo daily for 24 weeks. The goal was to see if the drug could improve daily symptoms like congestion, run…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Healthy volunteers test two inhaled drug versions for better absorption
Knowledge-focused CompletedThis study tested two different versions of an inhaled drug (TPIP) in 42 healthy adults to see how much of the drug gets into the blood. Participants inhaled a single dose of each version on separate days. The results help researchers understand which formulation works better for…
Phase: PHASE1 • Sponsor: Insmed Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC